advertisement

---

Srinivasan K 11

Showing records 1 to 11 | Display all abstracts from Srinivasan K

98747 Access to eye care during the COVID-19 pandemic, India
Muralikrishnan J
Bulletin of the World Health Organisation 2022; 100: 135-143

---

98905 Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial
Shankar LG
Ophthalmology. Glaucoma 2022; 5: 516-524

---

98747 Access to eye care during the COVID-19 pandemic, India
Christy JS
Bulletin of the World Health Organisation 2022; 100: 135-143

---

98905 Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial
Odayappan A; Shukla AG; Shukla AG
Ophthalmology. Glaucoma 2022; 5: 516-524

---

98747 Access to eye care during the COVID-19 pandemic, India
Srinivasan K
Bulletin of the World Health Organisation 2022; 100: 135-143

---

98905 Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial
Ramaswamy VC
Ophthalmology. Glaucoma 2022; 5: 516-524

---

98747 Access to eye care during the COVID-19 pandemic, India
Subburaman GB; Shukla AG; Shukla AG
Bulletin of the World Health Organisation 2022; 100: 135-143

---

98905 Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial
Rengaraj V
Ophthalmology. Glaucoma 2022; 5: 516-524

---

98747 Access to eye care during the COVID-19 pandemic, India
Venkatesh R
Bulletin of the World Health Organisation 2022; 100: 135-143

---

98905 Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial
Srinivasan K
Ophthalmology. Glaucoma 2022; 5: 516-524

---

98747 Access to eye care during the COVID-19 pandemic, India
Ravilla TD
Bulletin of the World Health Organisation 2022; 100: 135-143

---